• 196
    Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 527.
  • 197
    Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52 (Suppl): 5432S5440S.
  • 198
    Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 26562675.
  • 199
    Shipp MA, Mauch PM, Harris NL: Non-Hodgkin's lymphomas, in DeVita VT Jr, Hellman
  • 200
    RosenbergSA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 21652219.
  • 201
    The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 21122135.
  • 202
    Skarin AT: Non-Hodgkin's lymphoma. Adv Intern Med 1989; 34: 209242.
  • 203
    Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 13611392.
  • 204
    Dehner LP: Here we go again: A new classification of malignant lymphomas: A viewpoint from the trenches. Am J Clin Pathol 1995; 103: 539540.
  • 205
    Pittaluga S, Bijnens L, Teodorovic I, et al: Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: A comparison with the Working Formulation. Blood 1996; 87: 43584367.
  • 206
    Grogan TM, Miller TP, Dahlberg S, et al: REAL classification of lymphoma allows improved delineation of histologic risk groups: A Southwest Oncology Group (SWOG) study. Proceedings of the American Society of Clinical Oncology 1996; 15: 425. Abstract.
  • 207
    Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 10521057.
  • 208
    Wagner SD, Martinelli V, Luzzatto L: Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994; 83: 36473653.
  • 209
    Offit K, Parsa NZ, Filippa D, et al: t(9;14)(p13;q32) Denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood 1992; 80: 25942599.
  • 210
    Weisenburger DD, Armitage JO: Mantle cell lymphoma—an entity comes of age. Blood 1996; 87: 44834494.
  • 211
    Offit K, Lo Coco F, Louie DC, et al: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 7480.
  • 212
    Sandlund JT, Downing JR, Crist WM: Non-Hodgkin's lymphoma in children. N Engl J Med 1996; 334: 12381248.
  • 213
    Yano T, van Krieken JHJM, Magrath IT, et al: Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 1992; 79: 12821290.
  • 214
    Armitage JO, Greer JP, Levine AM, et al: Peripheral T-cell lymphoma. Cancer 1989; 63: 158163.
  • 215
    Pinkus GS, O'Hara CJ, Said JW: Peripheral/post-thymic T-cell lymphomas: A spectrum of disease: Clinical, pathologic, and immunologic features of 78 cases. Cancer 1990; 65: 971998.
  • 216
    Kadin ME: Primary ki-1-positive anaplastic large-cell lymphoma—A distinct clinicopathologic entity. Ann Oncol 1994; 5 (Suppl 1): 2530.
  • 217
    Berliner N, Ault KA, Martin P, et al: Detection of clonal excess in lymphoproliferative disease by kappa/lambda analysis: Correlation with immunoglobulin gene DNA rearrangement. Blood 1986; 67: 8085.
  • 218
    Fisher DE, Jacobson JO, Ault KA, et al: Diffuse large cell lymphoma with discordant bone marrow histology: Clinical features and biological implications. Cancer 1989; 64: 18791887.
  • 219
    Kilo MN, Dorfman DM: The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 1996; 105: 451457.
  • 220
    Kaplan WD, Jochelson MS, Herman TS, et al: Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 19661970.
  • 221
    Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has “high-risk” disease? Blood 1994; 83: 11651173.
  • 222
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987994.
  • 223
    Hermans JvGK, Krol AD, van Groningen K, et al: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 14601463.
  • 224
    Janicek M, Kaplan W, Neuberg D, et al: Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 16311637. Abstract.
  • 225
    Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al: Clinical stage I non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 10881093.
  • 226
    Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 12821290.
  • 227
    Rosenberg SA: The low-grade non-Hodgkin's lymphomas: Challenges and opportunities. J Clin Oncol 1985; 3: 299310.
  • 228
    Brice P, Solal-Celigny P, Lepage E, et al: A randomized study in low tumor burden follicular lymphoma between no treatment, prednimustine and interferon. Proceedings of the American Society of Clinical Oncology 1995; 14: 394. Abstract.
  • 229
    Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 27802786.
  • 230
    Grossbard ML, Fidias P: Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Clin Immunol Immunopathol 1995; 76: 107114.
  • 231
    Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphproliferative disorders. Blood 1995; 86: 24632474.
  • 232
    Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514519.
  • 233
    Connors JM, Klimo P, Fairey RN, et al: Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma. Ann Intern Med 1987; 107: 2530.
  • 234
    Miller TP, Dahlberg S, Cassady JR, et al: Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group Study. Proceedings of the American Society of Clinical Oncology 1996; 15: 411. Abstract.
  • 235
    Glick JH, Kim K, Earle J, et al: An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). Proceedings of the American Society of Clinical Oncology 1996; 14: 391. Abstract.
  • 236
    Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 10021006.
  • 237
    Shipp MA, Neuberg D, Janicek M, et al: Highdose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995; 13: 29162923.
  • 238
    Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994; 12: 25432551.
  • 239
    Haioun C, Lepage E, Gisselbrecht C, et al: Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): A study of 542 patients (LNH87–2 Protocol). Blood 1995; 86: 457. Abstract.
  • 240
    Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117122.
  • 241
    Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 15731582.
  • 242
    Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 15401545.
  • 243
    Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925934.
  • 244
    Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults: A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664674.
  • 245
    Coleman CN, Picozzi VJ Jr, Cox RS, et al: Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 16281637.
  • 246
    Baro J, Richard C, Sierra J, et al: Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992; 10: 3338.
  • 247
    The International Non-Hodgkin's Lymphoma Classification Project: Application of the International Lymphoma Study Group (ILSG) classification of non-Hodgkin's lymphoma (NHL): Clinical characteristics and outcome of 1400 patients from 8 countries. Ann Oncol 1996; 7 (Suppl 3): 2. Abstract.
  • 248
    Rogers J, Jackson J, Rosenberg J, et al: Clearance of BCL-2 (t14;18) from peripheral blood (PB) and bone marrow in patients (PTS) with relapsed low-grade or follicular (IWF:A-D) lymphoma (NHL) following single-agent therapy with the chimeric anti-CD20 antibody (MAB) IDEC-C2B8. Ann Oncol 1996; 7 (Suppl 3): 34.
  • 249
    Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-Anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 19741981.
  • 250
    Schultze J, Cardoso A, Boussiotis V, et al: Generation of anti-follicular lymphoma specific T-cell mediated immunity. Ann Oncol 1996; 7 (Suppl 3): 19. Abstract.
  • 251
    Webb A, Cunningham D, Cotter F, et al: Phase I BCL-2 antisense trial: Preliminary results. Ann Oncol 1996; 7 (Suppl 3): 32. Abstract.
  • 252
    Alcorn MJ, Holyoake TL, Richmond L, et al: CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996; 14: 18391847.
  • 253
    Shipp MA: Can we improve upon the International index? Ann Oncol 1996; 7 (Suppl 3): 11. Abstract.
  • 254
    Skarin AT, Dorfman DM: Hodgkin's disease and non-Hodgkin's lymphomas, in SkarinAT: Atlas of Diagnostic Oncology, ed 2. London, Mosby-Wolfe, 1996, pp 465525.